Imatinib mesylate in chordoma (Q28282621)

6

0 references

Paolo Giovanni Casali

1

0 references

Silvana Pilotti

18

0 references

Elena Tamborini

4

0 references

Carlo Spreafico

9

0 references

Antonella Messina

2

0 references

Elena Rosa Fumagalli

Elena Fumagalli

13

0 references

Rosaria Orlandi

Rosaria Orlandi

7

0 references

Rossella Bertulli

Rossella Bertulli

11

0 references

Angela Greco

Angela Greco

14

0 references

Maurizio Colecchia

Maurizio Colecchia

12

0 references

Carla Ripamonti

Carla Ripamonti

8

0 references

Marco A. Pierotti

Marco A Pierotti

17

0 references

Federica Grosso

15

Federica Grosso

0 references

author name string

Flavio Crippa

5

0 references

Raffaello Bertieri

10

0 references

Patrizia Olmi

Chordoma: incidence and survival patterns in the United States, 1973-1995.

16

0 references

language of work or name

English

0 references

publication date

1 November 2004

0 references

published in

Cancer

0 references

volume

101

0 references

issue

9

0 references

page(s)

2086-97

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Chordoma: natural history and results in 28 patients treated at a single institution.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

High amputation of the sacrum for extirpation of tumors. Principles and technique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Sacral chordoma: 40-year experience at a major cancer center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Proton radiation therapy for chordomas and chondrosarcomas of the skull base

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Chordoma: Natural history and treatment results in 33 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Chemotherapeutic treatment of malignant chordoma in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021

Management of malignant gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20618

7 January 2021